[KongchangAI]
Unverified50% confidenceFactExact time

The EU MDR classifies diagnostic AI as a high-risk medical device requiring notified body involvement; China's NMPA manages AI-assisted diagnostic software as Class III medical devices and requires clinical trial data.

1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/22/2026
First Seen
Valid until: 1/20/2027

Sources

Microsoft's AI Diagnostic Tool Four Times More Accurate Than Doctors? An In-Depth Analysis

Related Entities

欧盟MDRconceptNMPAcompany

Related Claims

UnverifiedFDA的SaMD框架将AI诊断工具按风险分为三类，III类需完整的上市前批准（PMA）并提交多中心临床试验数据78% similarUnverifiedRegulators (such as the U.S. FDA and China's NMPA) typically require prospective data, or at least rigorously designed multicenter retrospective validation, for high-risk diagnostic AI.75% similar

Cite This Claim

Stable URI
https://kongchang.com/claim/1086556
API
curl https://kongchang.com/api/v1/knowledge/claims/1086556
MCP
get_claim(id=1086556)